Page 86 - GPD-4-2

Gene & Protein in Disease Alport syndrome: Genetics, variability, and management

53. Study Details - Study of Hydroxychloroquine in Patients With Nephrol. 2022;17(12):1713.
X-linked Alport Syndrome in China (CHXLAS). Available doi: 10.2215/CJN.12491022
from: https://clinicaltrials.gov/study/NCT04937907 [Last
accessed on 2024 Dec 14]. 57. Yamamura T, Horinouchi T, Adachi T, et al. Development
of an exon skipping therapy for X-linked Alport syndrome
54. Warady BA, Pergola PE, Agarwal R, et al. Effects of with truncating variants in COL4A5. Nat Commun.
bardoxolone methyl in alport syndrome. Clin J Am Soc
Nephrol. 2022;17(12):1763-1774. 2020;11(1):2777.
doi: 10.1038/S41467-020-16605-X
doi: 10.2215/CJN.02400222/-/DCSUPPLEMENTAL
58. Cox DBT, Platt RJ, Zhang F. Therapeutic genome editing:
55. Chertow GM, Appel GB, Andreoli S, et al. Study design and
baseline characteristics of the CARDINAL trial: A phase Prospects and challenges. Nat Med. 2015;21(2):121-131.
3 study of bardoxolone methyl in patients with alport doi: 10.1038/NM.3793
syndrome. Am J Nephrol. 2021;52(3):180-189.
59. Daga S, Donati F, Capitani K, et al. New frontiers to cure
doi: 10.1159/000513777 Alport syndrome: COL4A3 and COL4A5 gene editing in
podocyte-lineage cells. Eur J Hum Genet. 2020;28(4):480-490.
56. Quinlan C, Jayasinghe K. Bardoxolone methyl for alport
syndrome: Opportunities and challenges. Clin J Am Soc doi: 10.1038/S41431-019-0537-8

Volume 4 Issue 2 (2025) 12 doi: 10.36922/gpd.7656